PROSENSA HOLDING N.V. SHAREHOLDER ALERT: Johnson & Weaver, LLP Reminds Investors of Upcoming September 16, 2014 Deadline;

  Investors of Upcoming September 16, 2014 Deadline; Encourages Investors with
  Significant Losses to Contact the Firm

Business Wire

SAN DIEGO -- July 26, 2014

Shareholder rights law firm Johnson & Weaver, LLP reminds investors of the
September 16, 2014 lead plaintiff deadline in a securities class action
lawsuit filed by the firm against Prosensa Holding N.V. (NASDAQ:RNA). The
class action lawsuit was filed in the United States District Court for the
Southern District of New York on behalf of the class (the “Class”). Those
purchasers of the ordinary common shares of Prosensa pursuant and/or traceable
to the Company's initial public offering (“IPO”) on or about June 28, 2013 and
suffered significant losses are encouraged to contact Johnson & Weaver
regarding your legal rights.

Prosensa is a biotechnology company engaged in the discovery and development
of RNA-modulating therapeutics for the treatment of genetic disorders. The
Company’s first and lead product candidate was drisapersen, which Prosensa was
developing in collaboration with GlaxoSmithKline to address a variety of
mutations resulting in inadequate production of dystrophin − a protein
necessary for muscle function.

Additional Information about the Lawsuit:

On September 20, 2013, less than three months after Prosensa’s June 2013 IPO,
the Company issued a joint press release with GlaxoSmithKline, disclosing that
drisapersen had not met the primary endpoint in the Phase III study. According
to the press release, “There was no treatment difference in key secondary
assessments of motor function: 10-meter walk/run test, 4-stair climb and North
Star Ambulatory Assessment.”

On this news, Prosensa stock declined approximately 70 percent, or $16.86 per
share, on unusually heavy trading volume, to close on September 20, 2013 at
$7.14 per share.

Prosensa and certain of its executives are charged with issuing a series of
materially false and misleading statements during the Class Period, violating
federal securities laws.

The Complaint alleges that the Registration Statement in Prosensa’s 2013 IPO
contained materially false and/or misleading statements and/or omitted
material information concerning the development status of drisapersen, the
drug’s Phase II and Phase III clinical studies, and the prospects for
drisapersen’s regulatory approval.

Plaintiff seeks to recover damages on behalf of all purchasers of Prosensa
publicly traded securities during the Class Period. If you wish to serve as a
lead plaintiff, you must move the Court no later than September 16, 2014. If
you wish to discuss this action, have any questions concerning this notice, or
your rights or interests, please contact lead analyst Jim Baker
( at 619-814-4471. If you email, please include your
phone number.

Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm
with offices in California, New York and Georgia. The firm represents
individual and institutional investors in shareholder derivative and
securities class action lawsuits. For more information about the firm and its
attorneys, please visit


Johnson & Weaver, LLP
Jim Baker, 619-814-4471
Press spacebar to pause and continue. Press esc to stop.